drugset / Trial / NCT05327231
IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase I, multi-center clinical trial to evaluate the safety, tolerability, antitumor activities and pharmacokinetics of IN10018 as monotherapy or in combination with docetaxel in previously-treated locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Timeline
- Start
- 2020-07-09
- Primary completion
- 2021-12-03
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ifebemtinib | Small molecule | 100 mg | Oral |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |